Assessing the benefits and risks to mothers and offspring of continuing treatment for maternal hypertension and hypothyroidism: an observational cohort study in the UK Clinical Practice Research Datalink
Preprint
Abstract
Exclusion of pregnant women from clinical trials, due to ethical concerns, has limited evidence on medication safety during pregnancy, resulting in conservative guidance. Yet, rising prevalence of chronic conditions in reproductive-age women has increased medication use. This study evaluates risks and benefits of discontinuing drug prescriptions for chronic hypertension, and hypothyroidism during pregnancy using linked primary care records from a longitudinal intergenerational database. Using UK Clinical Practice Research Datalink (CPRD) GOLD, we conducted multivariable regression models, adjusted for covariates, to assess maternal treatment discontinuation on various outcomes. Cohorts of 3,232 and 3,334 pregnancies with chronic hypertension and hypothyroidism respectively were derived from the CPRD. Discontinuing vasodilator antihypertensive drugs for hypertension was associated with increased gestational age (mean difference: 3.98 weeks, 95% CI: 1.61, 6.35). Estimated associations between other antihypertensives (calcium-channel blockers, diuretics or renin-angiotensin system drugs) and any study outcome crossed the null. Discontinuing thyroid hormones for hypothyroidism were associated with reduced the odds of miscarriage (OR: 0.29, 95% CI: 0.15, 0.54) and increased gestational age (mean difference 1.84 weeks, 95% CI: 0.12, 3.57). Results were robust in sensitivity analysis. This study reports a reassuring lack of association between many drug subclasses and adverse offspring outcomes. This evidence of potential risk associated with treatment discontinuation may guide clinical decision-making for treating chronic hypertension and hypothyroidism during pregnancy in similar populations.Keywords
This publication has 44 references indexed in Scilit:
- Drug development research in pregnant and lactating womenAmerican Journal of Obstetrics and Gynecology, 2021
- Recurrent miscarriage: evidence to accelerate actionThe Lancet, 2021
- Anatomical and physiological alterations of pregnancyJournal of Pharmacokinetics and Pharmacodynamics, 2020
- The flipside of hydralazine in pregnancy: A systematic review and meta-analysisPregnancy Hypertension, 2020
- Methods to generate and validate a Pregnancy Register in the UK Clinical Practice Research Datalink primary care databasePharmacoepidemiology and Drug Safety, 2019
- Trends in pregnancy labeling and data quality for US-approved pharmaceuticalsAmerican Journal of Obstetrics and Gynecology, 2014
- Drug Treatment of Hypertension in PregnancyDrugs, 2014
- Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK General Practice Research DatabasePharmacoepidemiology and Drug Safety, 2006
- An application of propensity score matching using claims dataPharmacoepidemiology and Drug Safety, 2005
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998